EX-99.07
8
ex99-07.htm
MAY 28, 2008 PRESS RELEASE
ex99-07.htm
Exhibit
99.07
HemCon
Medical
Technologies Inc.
FOR
IMMEDIATE RELEASE
Public
Relations Contact:
David
Chatham
Capstrat
for HemCon Medical Technologies Inc.
919-882-1954
dchatham@capstrat.com
HemCon
Medical Technologies Leverages Sangui Technology to Expand its Wound Care
Product Line
PORTLAND, Ore. - May 28, 2008 -
HemCon Medical Technologies Inc. today announced it will use Witten,
Germany-based SanguiBioTech GmbH's ChitoSkin technology platform to help further
innovations in hemostatic bandages and wound care dressings for the acute care
market.
Under the
terms of the agreement, HemCon will leverage Sangui's technology platform to
enhance and expand its product offerings for surgical and wound
care. HemCon developed the chitosan-based hemostatic HemCon® Bandages
and ChitoFlex® dressings that are used by military and medical first responders
as well as health care professionals around the globe.
"We
explored a wide variety of technology platforms to add to our new surgical and
wound care offerings and feel that the Sangui chitosan platform offers great
opportunities to enhance our solutions", said John W. Morgan, president and CEO
of HemCon. "We're committed to continuing our investment to develop
new choices for medical professionals and consumers. This agreement
is an important step forward in realizing the full potential of chitosan-based
products."
SanguiBioTech
GmbH is a wholly owned subsidiary of Sangui BioTech International,
Inc. Sangui BioTech International focuses on vascular and hemostasis
products. The firm specializes in developing oxygen-carrying agents
to treat blocked arteries, anemia or acute blood loss through SanguiBioTech
GmbH.
"We are
proud to enter into an agreement with HemCon and offer our chitosan platform to
help innovate new surgical and wound care products", said Sangui Managing
Director Hubertus Schmelz. "There is definitely a demand for products
that can adapt to specific medical needs, especially as it relates to wound
care."
HemCon
retains exclusive worldwide market and distribution rights for products
developed under this structured financial agreement. HemCon will
submit developed products for U.S. approvals to the FDA, while Sangui will
prepare documentation for registration in the European Union.
About
HemCon Medical Technologies Inc.
HemCon
Medical Technologies Inc., founded in 2001, develops, manufactures and markets
innovative products and technologies to improve patient care and control
infection. The flagship hemostatic HemCon dressings are used by
military and civilian first responders as well as medical professionals in
hospital, dental, and clinical settings where rapid control of bleeding is of
critical importance. In addition HemCon develops and licenses unique
technology platforms and delivery systems for use in the cosmeceutical, wound
care, and cardiovascular health markets. Synpart, a wholly-owned,
European subsidiary of HemCon is a leading designer and manufacturer of general
oral care products. HemCon corporate headquarters reside in Portland,
Oregon with additional commercial operation in Ireland; England; Germany and the
Czech Republic. For more information, please visit
www.hemcon.com
.
About
SanguiBioTech GmbH
SanguiBioTech
GmbH is a wholly-owned subsidiary of Sangui BioTech International, Inc. (
www.pinksheets.com
:
SGBI). Established in 1995, the company focuses on improving the
oxygen supply to the human body. The company has developed a range of
products providing oxygen to the healthy as well as to the damaged skin and
distributes medicosmetics as well as wound management products in Europe and
other international markets. One of its core technologies is the
patented Chitoskin technology range, a unique and multi purpose chitosan based
wound dressing family.

EX - 99 . 07 8 ex99 - 07 . htm MAY 28 , 2008 PRESS RELEASE ex99 - 07 . htm Exhibit 99 . 07 HemCon Medical Technologies Inc . FOR IMMEDIATE RELEASE Public Relations Contact : David Chatham Capstrat for HemCon Medical Technologies Inc . 919 - 882 - 1954 dchatham@capstrat.com HemCon Medical Technologies Leverages Sangui Technology to Expand its Wound Care Product Line PORTLAND , Ore . - May 28 , 2008 - HemCon Medical Technologies Inc . today announced it will use Witten , Germany - based SanguiBioTech GmbH 's ChitoSkin technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute care market . Under the terms of the agreement , HemCon will leverage Sangui 's technology platform to enhance and expand its product offerings for surgical and wound care . HemCon developed the chitosan - based hemostatic HemCon ® Bandages and ChitoFlex ® dressings that are used by military and medical first responders as well as health care professionals around the globe . " We explored a wide variety of technology platforms to add to our new surgical and wound care offerings and feel that the Sangui chitosan platform offers great opportunities to enhance our solutions " , said John W . Morgan , president and CEO of HemCon . " We ' re committed to continuing our investment to develop new choices for medical professionals and consumers . This agreement is an important step forward in realizing the full potential of chitosan - based products . " SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International , Inc . Sangui BioTech International focuses on vascular and hemostasis products . The firm specializes in developing oxygen - carrying agents to treat blocked arteries , anemia or acute blood loss through SanguiBioTech GmbH . " We are proud to enter into an agreement with HemCon and offer our chitosan platform to help innovate new surgical and wound care products " , said Sangui Managing Director Hubertus Schmelz . " There is definitely a demand for products that can adapt to specific medical needs , especially as it relates to wound care . " HemCon retains exclusive worldwide market and distribution rights for products developed under this structured financial agreement . HemCon will submit developed products for U . S . approvals to the FDA , while Sangui will prepare documentation for registration in the European Union . About HemCon Medical Technologies Inc . HemCon Medical Technologies Inc . , founded in 2001 , develops , manufactures and markets innovative products and technologies to improve patient care and control infection . The flagship hemostatic HemCon dressings are used by military and civilian first responders as well as medical professionals in hospital , dental , and clinical settings where rapid control of bleeding is of critical importance . In addition HemCon develops and licenses unique technology platforms and delivery systems for use in the cosmeceutical , wound care , and cardiovascular health markets . Synpart , a wholly - owned , European subsidiary of HemCon is a leading designer and manufacturer of general oral care products . HemCon corporate headquarters reside in Portland , Oregon with additional commercial operation in Ireland ; England ; Germany and the Czech Republic . For more information , please visit www.hemcon.com . About SanguiBioTech GmbH SanguiBioTech GmbH is a wholly - owned subsidiary of Sangui BioTech International , Inc . ( www.pinksheets.com : SGBI ) . Established in 1995 , the company focuses on improving the oxygen supply to the human body . The company has developed a range of products providing oxygen to the healthy as well as to the damaged skin and distributes medicosmetics as well as wound management products in Europe and other international markets . One of its core technologies is the patented Chitoskin technology range , a unique and multi purpose chitosan based wound dressing family .